Last reviewed · How we verify
Remazolam
At a glance
| Generic name | Remazolam |
|---|---|
| Also known as | Yichang Humanwell Pharmaceutical Company, Yichang Humanwell |
| Sponsor | Sichuan Provincial People's Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients (PHASE4)
- A Non-intervention Fiberoptic Bronchoscopy Study of Remazolam Toluene Sulfonate for Injection Under General Anesthesia and Fiberoptic Bronchoscopy
- A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
- Correlation Between Neurofilament Light Chain and Remazolam Sensitivity in Elderly Adults (EARLY_PHASE1)
- Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery (NA)
- Effect of Remazolam Besylate Combined With Remifentanil Analgesic Sedation on the Prognosis of Patients With Sepsis (PHASE4)
- Effect of Remazolam on Hemodynamics During Hepatectomy (PHASE4)
- The Application of Remazolam in Gastroenteroscopy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remazolam CI brief — competitive landscape report
- Remazolam updates RSS · CI watch RSS
- Sichuan Provincial People's Hospital portfolio CI